Protalix BioTherapeutics, Inc.
PLX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001006281
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Dec 23, 2025 | Dec 19, 2025 | Bashan DrorPRESIDENT AND CEO | PPurchaseCommon Stock | +56K | $1.81 | +$101.36K | 188.52K | +42.3% | SEC |
| Nov 19, 2025 | Nov 18, 2025 | Bar-Shalev AmosDirector | SSaleCommon Stock | −168 | $1.87 | −$314.16 | 0 | −100.0% | SEC |
| Aug 12, 2025 | Jun 10, 2025 | Schwartz AharonDirector | PPurchaseCommon Stock | +129K | $1.60 | +$206.4K | 303K | +74.1% | SEC |
| Oct 20, 2023 | Oct 19, 2023 | Bashan DrorPRESIDENT AND CEO | PPurchaseCommon Stock | +64.52K | $1.4025 | +$90.48K | 132.52K | +94.9% | SEC |
| Jan 5, 2023 | Jan 3, 2023 | Schwartz AharonDirector | PPurchaseCommon Stock | +110K | $1.42 | +$156.2K | 174K | +171.9% | SEC |
| Apr 13, 2022 | Apr 11, 2022 | Bashan DrorPresident and CEO | PPurchaseCommon Stock | +68K | $1.50 | +$102K | 68K | New position | SEC |